ALAnqi Li

Anqi Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anqi Li has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Fernando Gonzalez-Ortiz

    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

    2 shared publications
  • Guanxun Cheng

    Department of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen, China

    2 shared publications
  • Jie Yang

    Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China

    2 shared publications
  • Kaj Blennow

    Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

    2 shared publications
  • Kun Sun

    Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China

    2 shared publications
  • Laihong Zhang

    Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China

    2 shared publications

Latest Publications

  • Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer’s disease in a multicenter and multiethnic aging population

    by Guoyu Lan, Mengjie Wang, Fernando Gonzalez-Ortiz, Laihong Zhang, Anqi Li, Binyin Li, Mingxing Jiang, Jie Yang, Xuhui Chen, Dai Shi, et al.

    Over 20% of patients with Alzheimer's disease (AD) worlwide are Chinese, although the efficacy of existing blood-based measures of AD biomarkers is largely unknown in Asian cohorts. Here we explored how plasma tau biomarkers correlated with cross-sectional and longitudinal AD-related outcomes and their diagnostic performance in 1,085 participants from three independent studies, including two Chinese cohorts, Greater-Bay-Area Healthy Aging Brain Study (n = 425) and Huashan (n = 297), and the North American Alzheimer's Disease Neuroimaging Initiative cohort (n = 363). Plasma p-tau217 performed best in classifying Aβ-positron emission tomography (PET) and tau-PET positivity throughout the AD continuum and correlated with all AD-related outcomes. A two-cutoff approach suggested that participants with intermediate plasma p-tau217 levels experienced rapid accumulation of Aβ-PET and entorhinal tau-PET, as well as accelerated hypometabolism and cognitive decline. Increased plasma p-tau217 was also associated with rapid longitudinal changes in Aβ-PET, tau-PET and neurodegeneration. These results suggest that plasma p-tau217 is superior in detecting multiple aspects of AD-related pathological changes and tracking disease progression.


  • Higher plasma soluble TREM2 correlates with reduced cerebral tau accumulation in Alzheimer’s disease

    by Guoyu Lan, Anqi Li, Fernando Gonzalez-Ortiz, Jieqin Lv, Wenqing Ran, Yue Cai, Pan Sun, Lin Liu, Jie Yang, Laihong Zhang, et al.

    Loss-of-function mutation of triggering receptor expressed on myeloid cell 2 (TREM2) is associated with increased risks for Alzheimer’s disease (AD). Recent animal studies reveal that the activation of peripheral TREM2 signaling may affect cerebral β-amyloid (Aβ) and tau aggregates. However, the underlying relationship between peripheral TREM2 and brain AD pathology has not yet been well-elucidated in the aging population. In this study, we collected 318 Chinese older adults with Aβ PET and plasma biomarker measures, including soluble TREM2 (sTREM2) and glial fibrillary acidic protein (GFAP), a proxy for astrocyte reactivity. Additionally, 129 participants underwent tau PET scans. We explored the association between plasma sTREM2, GFAP, and primary AD pathology. Plasma sTREM2 was negatively associated with reduced temporal tau PET burden in participants with abnormal Aβ and tau pathology. Higher plasma sTREM2 was related to the weaker association of Aβ pathology and plasma phosphorylated tau with tau PET increases. In contrast, elevated plasma GFAP was related to greater Aβ and tau PET burden along with stronger Aβ-related tau accumulation. Finally, higher plasma sTREM2 was linked to attenuated strength of the association between plasma GFAP and tau PET increases at both pre-defined regions of interest and voxel levels. Altogether, our findings suggest distinct relationships between plasma sTREM2 and GFAP with cerebral tau pathology, providing novel insights into the roles of peripheral TREM2 signaling and astrocytic reactivity in AD neuropathological development. This study has important implications, such as targeting the peripheral TREM2 signature, which may be a potential strategy for future AD therapies.